Fulcrum Therapeutics Q1 2026 Earnings Narrowing Losses as Pipeline Advances RH Q1 2026 Earnings EPS Misses Estimates Stock Declines Amid Luxury Market Challenges CLNN Q1 2026 Earnings Narrowed Loss Beats Expectations Amid Ongoing Clinical Progress ODD Q4 2025 Earnings EPS Surges Past Estimates as Profitability Improves ASUR Q1 2026 Earnings EPS Surpasses Estimates by 183 Recurring Revenue Growth Drives Profitability TFX Q1 2026 Earnings EPS Surprises to the Upside with 1411 Beat Stock Edges Lower